The present invention relates to the field of allergens and more specifically to a novel isolated allergen from the species Cupressaceae shown to be a primary sensitizer for severe peach allergy mediated by the protein Pru p7. The allergen is homologous with Pru P7 in peach, a protein belonging to the Gibberelin Regulating Proteins (GRPs). The novel allergen also shares high sequence homology among other species from the Cupressaceae family and there is therefore also provided additional novel allergens in two other species of the Cupressaceae family. The novel allergens find use in the in vitro diagnosis of, treatment and/or prevention of Type 1 Cupressaceace pollen allergy and Cupressaceace pollen-associated food allergies.
The present invention relates to the field of allergens and more specifically to novel allergen isoform variants of Cup s 7 and related allergens containing an isoleucine in position 23. The novel allergen isoform variants find use in the in vitro diagnosis of, treatment and/or prevention of Type I Cupressaceace pollen allergy and Cupressaceace pollen-associated food allergies.
The present invention relates to a dispenser system (200) and a dispenser device (100) for dispensing a vessel (110) from a nested stack of vessels (110) in a hollow carrier (120) The invention also relates to the use of such a dispenser system (200) or dispenser device (100) for dispensing a vessel (110). The invention further relates to a method for manufacturing such a dispenser system (200).
PROTEIN BIOMARKERS FOR USE IN METHODS FOR THE DIAGNOSIS OR PROGNOSIS OF CHRONIC AIRFLOW LIMITATION (CAL) AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
The present invention relates to a method for indicating the presence or absence of Chronic Airflow Limitation (CAL) and/or for determining a predisposition to develop CORD, by determining the concentration of the biomarkers Alpha-1-acid glycoprotein 1 (AGP1) and Histidine-Rich Glycoprotein (HRG), optionally in combination with the biomarker Alpha-1-antitrypsin (a1AT) in said individuals. The present invention is also directed to a method for indicating the presence or absence of Chronic Obstructive Pulmonary Disease (COPD). These findings make it possible to identify individuals and attend to preventive measures before the progress of severe COPD disease in said individuals, but also at a more progressed state of COPD disease.
The present invention relates to the field of allergens and more specifically to a novel isolated allergen from the species Cupressaceae shown to be a primary sensitizer for severe peach allergy mediated by the protein Pru p7. The allergen is homologous with Pru P7 in peach, a protein belonging to the Gibberelin Regulating Proteins (GRPs). The novel allergen also 5 shares high sequence homology among other species from the Cupressaceae family and there is therefore also provided additional novel allergens in two other species of the Cupressaceae family. The novel allergens find use in the in vitro diagnosis of, treatment and/or prevention of Type 1 Cupressaceace pollen allergy and Cupressaceace pollen-associated food allergies.
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
Goods & Services
Providing reference materials, namely, providing online
electronic publications, not downloadable, in the fields of
allergies and autoimmune diseases to clinical laboratories. Analytical services, namely, quality evaluation and
assessment of clinical test performance and maintenance of
good laboratory practices.
01 - Chemical and biological materials for industrial, scientific and agricultural use
Goods & Services
Kits containing samples comprising components of human sera,
including immunoglobulins, for specific detection of
allergens and/or protein markers related to autoimmune
disorders for analytical, research and scientific use.
Methods for harmonization of test results from a biological sample in a multiplexed biochemical assay, wherein presence and/or concentration of multiple biomarkers are determined at the same time in the same sample, making test results obtained in different laboratories comparable comprise: quantifying a presence or concentration of at least two different biomarkers in a biological sample and in a harmonization standard sample, independently in each sample, by means of a defined multiplexed biochemical assay implemented in a defined type of analytical instrument; receiving the test results from the samples into a computer-based decision engine for harmonization of test results from biological samples; and transforming the test results received from the biological sample, which includes transforming the test results from the harmonization standard sample into generalized units and adjusting the test results of the biological sample into the generalized units, GE.
G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
The present invention relates to the field of allergens and more specifically to a novel isolated allergen from the species Cupressaceae shown to be a primary sensitizer for severe peach allergy mediated by the protein Pru p7. The allergen is homologous with Pru P7 in peach, a protein belonging to the Gibberelin Regulating Proteins (GRPs). The novel allergen also5 shares high sequence homology among other species from the Cupressaceae family and there is therefore also provided additional novel allergens in two other species of the Cupressaceae family. The novel allergens find use in the in vitro diagnosis of, treatment and/or prevention of Type 1 Cupressaceace pollen allergy and Cupressaceace pollen- associated food allergies.
The present invention relates generally to the detection and identification of various forms of genetic markers, and various forms of proteins, which have the potential utility as diagnostic markers. By determining the level of a plurality of biomarkers and genetic markers in a patient sample, and combining the obtained values according to a predefined formula, it is possible to determine if it is likely that the patient suffers from prostate cancer or aggressive prostate cancer. The method is improved by distinguishing between genetic subpopulations with a particularly high risk for prostate cancer or aggressive prostate cancer.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
Methods for harmonization of test results from a biological sample in a multiplexed biochemical assay, wherein presence and/or concentration of multiple biomarkers are determined at the same time in the same sample, making test results obtained in different laboratories comparable comprise: quantifying a presence or concentration of at least two different biomarkers in a biological sample and in a harmonization standard sample, independently in each sample, by means of a defined multiplexed biochemical assay implemented in a defined type of analytical instrument; receiving the test results from the samples into a computer-based decision engine for harmonization of test results from biological samples; and transforming the test results received from the biological sample, which includes transforming the test results from the harmonization standard sample into generalized units and adjusting the test results of the biological sample into the generalized units, GE.
G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
G06F 5/01 - Methods or arrangements for data conversion without changing the order or content of the data handled for shifting, e.g. justifying, scaling, normalising
16.
METHOD FOR INDICATING A PRESENCE OR NON-PRESENCE OF PROSTATE CANCER IN INDIVIDUALS WITH PARTICULAR CHARACTERISTICS
The present invention relates generally to the detection and identification of various forms of genetic markers, and various forms of proteins, which have the potential utility as diagnostic markers. By determining the level of a plurality of biomarkers and genetic markers in a patient sample, and combining the obtained values according to a predefined formula, it is possible to determine if it is likely that the patient suffers from prostate cancer or aggressive prostate cancer. The method is improved by distinguishing between genetic subpopulations with a particularly high risk for prostate cancer or aggressive prostate cancer.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
The invention relates to a novel horse allergen consisting of a heterodimeric protein having a first peptide chain and a second peptide chain together having an overall sequence identity of at least 70% with the combined sequences of SEQ ID NO:3 and SEQ ID NO: 4, as well as a single chain protein having an overall sequence identity of at least 70%, such as 75%, 80%, 85%, 90%, 95%, or 98%, with the combined amino acid sequences according to SEQ ID NO: 3 and SEQ ID NO: 4. The invention further relates to the use of the protein in methods of diagnosis and therapy of Type I allergy, and kits and compositions for use in such methods.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
A method for indicating a presence or non-presence of a predefined solid tumor cancer in an individual, comprising the steps of: A. Providing at least one biological sample originating from said individual at a first point in time; B. Providing at least one biological sample originating from said individual at a second point in time; C. In said at least two biological samples, measuring a presence or concentration of at least one biomarker related to said predefined solid tumor cancer; D. Combining data regarding the presence or concentration of the at least one biomarker to form a kinetic composite value that reflects the change of biomarker presence or concentration; E. Correlating the kinetic composite value to the presence or non-presence of said predefined solid tumor cancer in said individual by comparing the kinetic composite value to a pre-determined cut-off value established with control samples of known predefined solid tumor cancer and benign disease diagnosis; wherein the time period between the first point in time and the second point in time is in the range from 0.5% to 25%, or more preferably in the range from 0.1% to 15%, of a typical tumor volume doubling time of said predefined solid tumor cancer; and the at least one biomarker determined is the same biomarker in each of the biological samples.
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G06F 19/00 - Digital computing or data processing equipment or methods, specially adapted for specific applications (specially adapted for specific functions G06F 17/00;data processing systems or methods specially adapted for administrative, commercial, financial, managerial, supervisory or forecasting purposes G06Q;healthcare informatics G16H)
Methods for producing an allergen composition, methods for in vitro diagnosis of type I allergy, and diagnostic kits for performing diagnosis employ Bos d 23k allergen of SEQ ID NO: 4, or the mature protein thereof, or a variant or fragment of the Bos d 23k allergen or the mature protein sharing epitopes for antibodies with the Bos d 23k allergen or the mature protein. Methods for treatment of a Type I allergy to a mammal and pharmaceutical compositions employ a Bos d 23k allergen of SEQ ID NO: 4, or the mature protein thereof, or a variant or fragment of the Bos d 23k allergen or the mature protein sharing epitopes for antibodies with the Bos d 23k allergen or the mature protein, wherein the Bos d 23k allergen, the mature protein, the variant or the fragment is modified to abrogate or attenuate its IgE binding response.
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
A method for performing in vitro diagnosis of type 1 allergy, comprises contacting an immunoglobulin-containing body fluid sample from a patient suspected of having Type 1 allergy with an immobilized horse allergen immobilized on a solid support, and detecting the presence, in the sample, of IgE antibodies specifically binding to the horse allergen, wherein the presence of such IgE antibodies specifically binding to the horse allergen is indicative of Type 1 allergy. A method for treatment of Type 1 allergy comprises administering to an individual susceptible to such treatment, the horse allergen, or a form of the horse allergen that is modified to abrogate or attenuate its IgE binding response. The horse allergen may be produced via a vector and a host cell comprising the vector.
G01N 33/542 - ImmunoassayBiospecific binding assayMaterials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
Methods for treatment of a Type I allergy in a mammal comprise administering to an individual in need of such treatment a polypeptide of SEQ ID NO: 1 or the mature protein, amino acids 25-260, of the polypeptide of SEQ ID NO: 1, or a fragment of the polypeptide or the mature protein, which fragment shares epitopes for antibodies with the polypeptide or the mature protein, respectively, or a hypoallergenic form thereof that is modified to abrogate or attenuate its IgE binding response. Diagnostic kits comprise the polypeptide of SEQ ID NO: 1 or the mature protein, amino acids 25-260, of the polypeptide of SEQ ID NO: 1, immobilized on a solid support.
The invention relates to a novel horse allergen consisting of a heterodimeric protein having a first peptide chain and a second peptide chain together having an overall sequence identity of at least 70 % with the combined sequences of SEQ ID NO:3 and SEQ ID NO: 4, as well as a single chain protein having an overall sequence identity of at least 70%, such as 75%, 80%, 85%, 90%, 95%, or 98%, with the combined amino acid sequences according to SEQ ID NO: 3 and SEQ ID NO: 4. The invention further relates to the use of the protein in methods of diagnosis and therapy of Type I allergy, and kits and compositions for use in such methods.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
The invention relates to a novel horse allergen consisting of a heterodimeric protein having a first peptide chain and a second peptide chain together having an overall sequence identity of at least 70 % with the combined sequences of SEQ ID NO:3 and SEQ ID NO: 4, as well as a single chain protein having an overall sequence identity of at least 70%, such as 75%, 80%, 85%, 90%, 95%, or 98%, with the combined amino acid sequences according to SEQ ID NO: 3 and SEQ ID NO: 4.The invention further relates to the use of the protein in methods of diagnosis and therapy of Type I allergy, and kits and compositions for use in such methods.
The present invention relates generally to the detection and identification of various forms of genetic markers, and various forms of proteins, which have the potential utility as diagnostic markers. By determining the level of a plurality of biomarkers and genetic markers in a patient sample, and combining the obtained values according to a predefined formula, it is possible to determine if it is likely that the patient suffers from aggressive prostate cancer. The present invention is particularly applicable only for patients having a body mass index value greater than 25.
G16B 20/00 - ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
25.
Prognostic method for individuals with prostate cancer
The present invention relates generally to the detection and identification of various forms of genetic markers, and various forms of proteins, which have the potential utility as diagnostic markers. By determining the level of a plurality of biomarkers and genetic markers in a patient sample, and combining the obtained values according to a predefined formula, it is possible to forecast if it is likely that the prostate cancer patient will require active therapy like radiation therapy or surgery. A method based on a redundantly designed combination of data is disclosed for estimating if prostate cancer is aggressive or indolent. Said method combines SNP data to form a composite value, wherein at least 5% of the SNPs can be disregarded.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G16B 40/00 - ICT specially adapted for biostatisticsICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
A method for indicating a presence or non-presence of a predefined solid tumor cancer in an individual, comprising the steps of: A. Providing at least one biological sample originating from said individual at a first point in time; B. Providing at least one biological sample originating from said individual at a second point in time; C. In said at least two biological samples, measuring a presence or concentration of at least one biomarker related to said predefined solid tumor cancer; D. Combining data regarding the presence or concentration of the at least one biomarker to form a kinetic composite value that reflects the change of biomarker presence or concentration; E. Correlating the kinetic composite value to the presence or non-presence of said predefined solid tumor cancer in said individual by comparing the kinetic composite value to a pre-determined cut-off value established with control samples of known predefined solid tumor cancer and benign disease diagnosis; wherein the time period between the first point in time and the second point in time is in the range from 0.5% to 25%, or more preferably in the range from 0.1% to 15%,of a typical tumor volume doubling time of said predefined solid tumor cancer; and the at least one biomarker determined is the same biomarker in each of the biological samples.
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
(1) Chemical products for diagnostic use namely chemical buffer solutions for in vitro use in biochemistry, clinical chemistry and microbiology; diagnostic preparations for scientific research purposes for the detection of cancer; diagnostic preparations namely diagnostic preparations for clinical laboratory use
(2) Chemical products for diagnostic use namely chemical buffer solutions for in vitro use in biochemistry, clinical chemistry and microbiology; diagnostic preparations for scientific research purposes for the detection of cancer; diagnostic preparations namely diagnostic preparations for clinical laboratory use
(3) Diagnostic preparations for medical research use; reagents for use in diagnostic tests for medical purposes namely diagnostic reagents for medical laboratory use; chemical test reagents for medical purposes namely reagents for the detection of cancer; diagnostic reagents for scientific research use for the detection of cancer
(4) Diagnostic preparations for medical research use; reagents for use in diagnostic tests for medical purposes namely diagnostic reagents for medical laboratory use; chemical test reagents for medical purposes namely reagents for the detection of cancer; diagnostic reagents for scientific research use for the detection of cancer
(5) Diagnostic measuring apparatus using using immunoassay and nucleic acid detection technology together with mathematical algorithms to measure cancer associated risks namely medical devices for the qualitative detection of antibodies in human specimens collected as plasma or dried blood spots, mass spectrometers, used for the detection of cancer
(6) Diagnostic measuring apparatus using using immunoassay and nucleic acid detection technology together with mathematical algorithms to measure cancer associated risks namely medical devices for the qualitative detection of antibodies in human specimens collected as plasma or dried blood spots, mass spectrometers, used for the detection of cancer (1) Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; clinical trials for others; testing of pharmaceuticals
(2) Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; clinical trials for others; testing of pharmaceuticals
(3) Medical services for testing of blood
(4) Medical services for testing of blood
The present invention relates to a method which may be used for the analysis of endogenously formed antibodies such as anti-drug antibodies (ADAs) or rheumatoid factor (RF) in a solution, which method comprises (a) contacting the solution with a solid phase to which e.g. IgG molecule(s) have been attached; (b) allowing the ADAs or RF to bind specifically to the attached molecule(s); (c) adding a labeled isotype- specific reagent capable of binding ADAs or RF; (d) removing any excess of reagent; and (f) detecting the label bound or unbound to determine directly or indirectly the presence or concentration of ADAs in the solution. The molecule(s) have been attached to the solid phase via a linker, which may be an organic molecule, an amino acid, a peptide, a protein a molecule of protein origin, a monosaccharide, an oligosaccharide or a polysaccharide. The method according to the invention may be used e.g. as an immunoassay for making clinical decisions in patient care, as well as in the development of new drugs.
Methods for in vitro diagnosis of type I allergy comprises the steps of contacting an immunoglobulin-containing body fluid sample from a patient suspected of having type I allergy with a variant or fragment of the mature protein, amino acids 25-260, of the polypeptide of SEQ ID NO: 1, which variant or fragment shares epitopes for antibodies with the mature protein, amino acids 25-260, of the polypeptide of SEQ ID NO: 1; and detecting the presence, in the sample, of IgE antibodies specifically binding to the variant or fragment. The presence of such IgE antibodies specifically binding to the variant or fragment is indicative of a type I allergy in the patient.
The present invention relates to a method for calibrating a multiplex assay, comprising: adding a calibration reagent to a solid phase on which a plurality of capturing agents are immobilized, adding a detection molecule which has a capacity to bind to the calibration reagent, detecting bound detection molecule, thereby creating a calibration curve, wherein the calibration reagent comprises at least two different binding molecules, wherein each binding molecule has a capacity to bind specifically to a capturing agent immobilized on the solid phase and a capacity to bind to a detection molecule. Further provided is a multiplex assay system comprising such a calibration reagent.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
G01N 33/96 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving blood or serum control standard
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
31.
METHOD FOR INDICATING A PRESENCE OR NON-PRESENCE OF AGGRESSIVE PROSTATE CANCER
The present invention relates generally to the detection and identification of various forms of genetic markers, and various forms of proteins, which have the potential utility as diagnostic markers. By determining the level of a plurality of biomarkers and genetic markers in a patient sample, and combining the obtained values according to a predefined formula, it is possible to determine if it is likely that the patient suffers from aggressive prostate cancer. The present invention is particularly applicable only for patients having a body mass index value greater than 25.
The present invention relates generally to the detection and identification of various forms of genetic markers, and various forms of proteins, which have the potential utility as diagnostic markers. By determining the level of a plurality of biomarkers and genetic markers in a patient sample, and combining the obtained values according to a predefined formula, it is possible to forecast if it is likely that the prostate cancer patient will require active therapy like radiation therapy or surgery. A method based on a redundantly designed combination of data is disclosed for estimating if prostate cancer is aggressive or indolent. Said method combines SNP data to form a composite value, wherein at least 5% of the SNPs can be disregarded.
The present invention relates generally to the detection and identification of various forms of genetic markers, and various forms of proteins, which have the potential utility as diagnostic markers. By determining the level of a plurality of biomarkers and genetic markers in a patient sample, and combining the obtained values according to a predefined formula, it is possible to determine if it is likely that the patient suffers from prostate cancer.
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
09 - Scientific and electric apparatus and instruments
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Chemicals used in industry and science, including chemical
reagents and diagnostic preparations for in vitro use in
laboratories and industry. Chemical reagents and diagnostic preparations for medical
purposes; chemical reagents and diagnostic preparations for
in vitro and in vivo use for medical purposes; in vitro
diagnostic tests for medical use. Computer software and analytical instruments for laboratory
use. Scientific and technological services and research and
design relating thereto. Medical services.
The present invention relates to a method for calibrating a multiplex assay, comprising: adding a calibration reagent to a solid phase on which a plurality of capturing agents are immobilised, adding a detection molecule which has a capacity to bind to the calibration reagent, detecting bound detection molecule, thereby creating a calibration curve, wherein the calibration reagent comprises at least two different binding molecules, wherein each binding molecule has a capacity to bind specifically to a capturing agent immobilised on the solid phase and a capacity to bind to a detection molecule. Further provided is a multiplex assay system comprising such a calibration reagent.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
G01N 33/96 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving blood or serum control standard
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
09 - Scientific and electric apparatus and instruments
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
(1) Chemicals used in industry and science, namely chemical reagents and diagnostic preparations for in vitro use in laboratories and industry namely chemicals for use in the pharmaceutical industry, diagnostic reagents for medical laboratory use; chemical reagents and diagnostic preparations for medical purposes namely diagnostic reagents for medical diagnostic and medical research use; chemical reagents and diagnostic preparations for in vitro and in vivo use for medical purposes namely reagents in liquid form for the diagnostic of allergies, asthma, autoimmune diseases; in vitro diagnostic tests for medical use namely test strips for the determination of chemical, biochemical and immunological substances in body fluids, namely blood and urine, cuvettes, cartridges for chemical and immunochemical reagents for in vitro diagnostic testing, test strips for use in in vitro diagnostic examinations; computer software and analytical instruments for laboratory use namely software used to detect and diagnose allergies, asthma and autoimmune diseases and to interpret information pertaining to allergies, asthma and autoimmune diseases. (1) Scientific and technological services and research and design relating thereto in the field of in vitro and in vivo diagnostic of allergies, asthma and autoimmune diseases; medical services namely medical counselling, medical diagnostic services, medical laboratory, medical research and testing services.
An isolated horse allergen is disclosed which is a secretoglobin having a molecular weight of 15 kDa under non-reducing conditions and comprising a first peptide chain having a molecular weight of about 5 kDa and a second peptide chain having a molecular weight of about 10 kDa linked together, and variants and fragments thereof sharing epitopes for antibodies therewith. The use of the allergen in diagnosis and therapy is also disclosed as well as a diagnostic kit and a pharmaceutical composition containing the allergen.
C07K 1/00 - General processes for the preparation of peptides
C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
C07K 17/00 - Carrier-bound or immobilised peptidesPreparation thereof
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
09 - Scientific and electric apparatus and instruments
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Chemicals used in industry and science, including chemical reagents and diagnostic preparations for in vitro use in laboratories and industry. Chemical reagents and diagnostic preparations for medical purposes; chemical reagents and diagnostic preparations for in vitro and in vivo use for medical purposes; in vitro diagnostic tests for medical use. Computer software and analytical instruments for laboratory use. Scientific and technological services and research and design relating thereto. Medical services.
39.
WHEAT ANTIGENS AND PEPTIDES FOR DIAGNOSIS OF WHEAT INDUCED HYPERSENSITIVITY
The present invention relates to the field of different wheat hypersensitivities, particularly with antigens and peptides for discrimination of different forms of these diseases. The invention relates to the identification of novel wheat allergens and the use thereof in therapy and diagnosis of celiac disease, dermatitis herpetiformis, and IgE-mediated allergy. Furthermore, the present invention provides the use of known peptides and proteins in therapy and diagnosis. The invention also relates to methods for diagnosis and treatment of celiac disease, dermatitis herpetiformis,and IgE-mediated allergy.
The present invention relates to a method for estimation of kinetic characteristics for the formation and dissociation of a complex using lateral flow. The present invention facilitates an easy to use method with high accuracy.
G01N 31/00 - Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroupsApparatus specially adapted for such methods
G06F 19/00 - Digital computing or data processing equipment or methods, specially adapted for specific applications (specially adapted for specific functions G06F 17/00;data processing systems or methods specially adapted for administrative, commercial, financial, managerial, supervisory or forecasting purposes G06Q;healthcare informatics G16H)
G01N 33/557 - ImmunoassayBiospecific binding assayMaterials therefor using kinetic measurement, i.e. time rate of progress of an antigen-antibody interaction
The present invention refers to the field of allergy. More specifically, the invention relates to the identification of new allergens from mammals and to diagnosis and treatment of allergy towards mammals. In particular the invention relates to a recombinantly produced canine allergen, Can f 4, or bovine allergen, Bos d 23k, or variants or fragments thereof sharing epitopes with the wildtype allergen, and the use thereof for the manufacture of a diagnostic composition as well as methods for in vitro diagnosis and treatment of allergy.
C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
C12N 5/02 - Propagation of single cells or cells in suspensionMaintenance thereofCulture media therefor
C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 1/00 - General processes for the preparation of peptides
C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
C07K 17/00 - Carrier-bound or immobilised peptidesPreparation thereof
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
05 - Pharmaceutical, veterinary and sanitary products
09 - Scientific and electric apparatus and instruments
35 - Advertising and business services
38 - Telecommunications services
Goods & Services
Diagnostic reagents to aid in the medical diagnosis of
allergic conditions. Computer software and databases. Processing, storing, controlling and managing of information
in databases. Providing access to databases.
A method of providing a clinical decision support in allergy diagnosis comprises the steps of: a) providing a body fluid sample from a patient, b) selecting (1 10) a plurality of allergens to be tested for in the sample, c) determining (120) for each allergen the concentration in the sample of at least one immunoglobulin directed against the allergen, d) transforming (130) each determined immunoglobulin concentration to a clinical effect value on a normalized scale common to allergens in general, e) assigning to each allergen tested for, based on known cross-reactivity information for the allergen, an allergen specificity value, representing the degree of cross-reactivity for the allergen, and f) presenting (140) determined clinical effect and allergen specificity values for each allergen, or a group or groups of the allergens. A computer-implemented method, a computer program product, and a patient information carrier device containing a diagnosis result are also disclosed.
An isolated horse allergen is disclosed which is a secretoglobin having a molecular weight of 15 kDa under non-reducing conditions and comprising a first peptide chain having a molecular weight of about 5 kDa and a second peptide chain having a molecular weight of about 10 kDa linked together, and variants and fragments thereof sharing epitopes for antibodies therewith. The use of the allergen in diagnosis and therapy is also disclosed as well as a diagnostic kit and a pharmaceutical composition containing the allergen.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
An isolated horse allergen is disclosed which is a secretoglobin having a molecular weight of 15 kDa under non-reducing conditions and comprising a first peptide chain having a molecular weight of about 5 kDa and a second peptide chain having a molecular weight of about 10 kDa linked together, and variants and fragments thereof sharing epitopes for antibodies therewith. The use of the allergen in diagnosis and therapy is also disclosed as well as a diagnostic kit and a pharmaceutical composition containing the allergen.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Chemical reagents and diagnostic preparations for in vitro
use in medical and veterinary laboratories; chemical
reagents for medical and veterinary purposes; diagnostic
preparations for medical purposes.
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Chemical reagents and preparations for in vitro use in
scientific laboratories and for use in the pharmaceutical
industry. Chemical reagents and diagnostic preparations for in vitro
use in medical and veterinary laboratories; chemical
reagents for medical and veterinary purposes; diagnostic
preparations for medical purposes.
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Chemical reagents and preparations for in vitro use in
scientific laboratories and for use in the pharmaceutical
industry. Chemical reagents and diagnostic preparations for in vitro
use in medical and veterinary laboratories; chemical
reagents for medical and veterinary purposes; diagnostic
preparations for medical purposes.
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Chemical reagents and diagnostic preparations for in vitro use in medical and veterinary laboratories. Diagnostic preparations for medical purposes. Diagnostic instruments and apparatus for medical and veterinary purposes.
05 - Pharmaceutical, veterinary and sanitary products
09 - Scientific and electric apparatus and instruments
35 - Advertising and business services
38 - Telecommunications services
Goods & Services
Diagnostic reagents to aid in the medical diagnosis of allergic conditions. Computer software and databases. Processing, storing, controlling and managing of information in databases. Providing access to databases.
A two step lateral flow assay method for identifying IgE antibodies in a sample comprises applying a sample to a sample port of a device, wherein the device is adapted to deliver the sample to a lateral flow matrix having a plurality of IgE antigen species immobilized at respective positions at a first location; allowing the sample to travel along the lateral flow matrix through the immobilized plurality of IgE antigen species to a second location downstream of the first location; and, after a predetermined period of time, applying liquid buffer to the lateral flow matrix to mobilize labeled reagent which is adapted to bind anti-IgE antibody and which is dried on the lateral flow matrix at a location upstream of the sample port delivery of the sample to the lateral flow matrix, and allowing labeled reagent mobilized by the liquid buffer to travel along the lateral flow matrix through the immobilized plurality of IgE antigen species and bind with any IgE antibody bound to the immobilized IgE antigen species, and to travel to a second location downstream of the first location where the mobilized labeled reagent causes a visible change to occur at the second location.
A method enables clinical decision support based on test results for a plurality of tested biomarkers. The method is executed by a data reduction module (15) and comprises the steps of receiving the test results from a testing facility (11); accessing a predefined structure in which available biomarkers are associated with hosts, at least one host being associated with a plurality of biomarkers; identifying a set of hosts by mapping the tested biomarkers to the structure; assigning a host value to each host in said set of hosts based on the test results of the tested biomarker(s) mapped to the host; and providing input data indicative of the set of hosts and the assigned host values for input to a computer-based decision engine (13) for generating the clinical decision support (12). The data reduction module (15) may be included in a system and implemented by computer-executable instructions running on a data processing device, such as a PC or a web server.
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Chemical reagents and preparations for in vitro use in scientific laboratories and for use in the pharmaceutical industry. Chemical reagents and diagnostic preparations for in vitro use in medical and veterinary laboratories; chemical reagents for medical and veterinary purposes; diagnostic preparations for medical purposes.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Chemical reagents and diagnostic preparations for in vitro use in medical and veterinary laboratories; chemical reagents for medical and veterinary purposes; diagnostic preparations for medical purposes.
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Chemical reagents and preparations for in vitro use in scientific laboratories and for use in the pharmaceutical industry. Chemical reagents and diagnostic preparations for in vitro use in medical and veterinary laboratories; chemical reagents for medical and veterinary purposes; diagnostic preparations for medical purposes.
56.
RECOMBINANTLY PRODUCED CANINE AND BOVINE ALLERGENS
The present invention refers to the field of allergy. More specifically, the invention relates to the identification of new allergens from mammals and to diagnosis and treatment of allergy towards mammals. In particular the invention relates to a recombinantly produced canine allergen, Can f 4, or bovine allergen, Bos d 23k, or variants or fragments thereof sharing epitopes with the wildtype allergen, and the use thereof for the manufacture of a diagnostic composition as well as methods for in vitro diagnosis and treatment of allergy.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
The present invention refers to the field of allergy. More specifically, the invention relates to the identification of new allergens from mammals and to diagnosis and treatment of allergy towards mammals. In particular the invention relates to a recombinantly produced canine allergen, Can f 4, or bovine allergen, Bos d 23k, or variants or fragments thereof sharing epitopes with the wildtype allergen, and the use thereof for the manufacture of a diagnostic composition as well as methods for in vitro diagnosis and treatment of allergy.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
The present invention relates to the field of IgE-mediated allergy, particularly occupational asthma such as bakers asthma. More specifically the invention relates to the identification of a novel wheat allergen and the use thereof in therapy and diagnosis of IgE-mediated allergy. Furthermore the present invention provides the use of known peptides and proteins in therapy and diagnosis. The invention also relates to methods for diagnosis and treatment of IgE-mediated allergy in mammals.
A read-out method for a diagnostic point-of-care assay device, the device including a read-out substrate having at least one response area capable of producing a colored indication of a response, the response area including a marker at least one marker whose color changes in response to binding of an analyte thereto and which is used for indication of response. The method includes registering an image of the response area; calculating a color saturation value S for the image using at least two distinct wavelengths; using the S-value for determining a result of the assay. A read-out system (10) for an allergy point-of-care assay device is described. The system includes an illumination device (12; 21, 22) capable of delivering at least two different wavelengths of light; a color image capturing device (14); a control unit (19) for calculating a color saturation value on images recorded by the color image capturing device.
Prostatic kallikrein for the manufacture of a diagnostic or pharmaceutical composition for diagnosis/treatment of type 1 allergy, especially allergy to dogs.
Methods for detecting acute kidney injury in an individual comprise (a) contacting a body fluid sample from the individual with an assay device including neutrophil gelatinase-associated lipocalin (NGAL) antibody and a detectable label, to allow complexing of NGAL protein in the sample with NGAL antibody, and determining an amount of complex formed between NGAL protein from the sample and NGAL antibody in the assay device using the detectable label, wherein NGAL antibody in the device has binding capacity with more than two NGAL protein epitopes, and wherein the amount of the formed complex represents a level of acute kidney injury. Methods for determining an origin of NGAL protein in a sample from an individual include the step of determining relative amounts of monomeric, dimeric and heterodimeric forms of NGAL protein in the sample and allow improved diagnosis and therefore better targeted treatment.
A method enables clinical decision support based on test results for a plurality of tested biomarkers. The method is executed by a data reduction module (15) and comprises the steps of receiving the test results from a testing facility (11); accessing a predefined structure in which available biomarkers are associated with hosts, at least one host being associated with a plurality of biomarkers; identifying a set of hosts by mapping the tested biomarkers to the structure; assigning a host value to each host in said set of hosts based on the test results of the tested biomarker(s) mapped to the host; and providing input data indicative of the set of hosts and the assigned host values for input to a computer-based decision engine (13) for generating the clinical decision support (12). The data reduction module (15) may be included in a system and implemented by computer-executable instructions running on a data processing device, such as a PC or a web server.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
G06F 19/00 - Digital computing or data processing equipment or methods, specially adapted for specific applications (specially adapted for specific functions G06F 17/00;data processing systems or methods specially adapted for administrative, commercial, financial, managerial, supervisory or forecasting purposes G06Q;healthcare informatics G16H)
The invention relates to the design of encoded microparticles. Specifically, certain novel design features which optimise the shape encoding of microparticles with a feature size accessible to low cost optical readers, and with approximately constant surface area, are provided and claimed.
B01J 19/00 - Chemical, physical or physico-chemical processes in generalTheir relevant apparatus
G06K 19/06 - Record carriers for use with machines and with at least a part designed to carry digital markings characterised by the kind of the digital marking, e.g. shape, nature, code
The present invention relates to the field of IgE-mediated allergy, particularly occupational asthma such as baker s asthma. More specifically the invention relates to the identification of a novel wheat allergen and the use thereof in therapy and diagnosis of IgE-mediated allergy. Furthermore the present invention provides the use of known peptides and proteins in therapy and diagnosis. The invention also relates to methods for diagnosis and treatment of IgE-mediated allergy in mammals.
The present invention relates to the field of allergic diseases, and especially to methods for assessing if symptoms in a patient are related to a hypersensitivity to a specific allergen. Furthermore the invention relates to a computer program product comprising means for controlling the steps of said methods for use with an apparatus for analysis of binding assays. The invention also relates to such an apparatus.
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
(1) Chemical reagents and diagnostic preparations for medical use in the diagnosis and monitoring of allergies; diagnostic instruments and apparatus for diagnosis and monitoring of allergies
The invention relates to a read-out method for a diagnostic point-of-care assay device, the device comprising a read-out substrate having at least one response area capable of producing a coloured indication of a response, the response area comprising a marker at least one marker the colour of which changes in response to binding of an analyte thereto and which is used for indication of response. The method comprises registering an image of said response area; calculating a colour saturation value S for said image using at least twodistinct wavelengths; using the S-value for determining a result of the assay. Also, the invention relates to a read-out system (10) for an allergy point-of-care assay device (17, 18). The system comprises an illumination device (12; 21, 22) capable of delivering at least two different wavelengths of light; a colour image capturing device (14); a control unit (19) for calculating a colour saturation value (S) on images recorded by the colour image capturing device.
Prostatic kallikrein for the manufacture of a diagnostic or pharmaceutical composition for diagnosis/treatment of type 1 allergy, especially allergy to dogs.
Prostatic kallikrein for the manufacture of a diagnostic or pharmaceutical composition for diagnosis/treatment of type 1 allergy, especially allergy to dogs.
05 - Pharmaceutical, veterinary and sanitary products
09 - Scientific and electric apparatus and instruments
10 - Medical apparatus and instruments
Goods & Services
(1) Diagnostic preparations NAMELY for medical DIAGNOSTIC USE, FOR MEDICAL LABORATORY USE, FOR MEDICAL RESEARCH USE; Medical and diagnostic apparatuses and instruments NAMELY IN VITRO TEST SYSTEMS FOR MEDICAL AND VETERINARY USE NAMELY SAMPLE DILUENTS.
(2) SOFTWARE USED TO DETECT DISEASES AND INTERPRET INFORMATION.
(3) Medical and diagnostic apparatuses and instruments NAMELY IN VITRO TEST SYSTEMS FOR MEDICAL AND VETERINARY USE NAMELY CALIBRATORS, DISPENSERS, PIPES, CARRIER RACKS, TRAYS, MICRO-PLATES, LABEL FOR SAMPLES, MICRO-PLATE COVERS, SAMPLE RACKS.
Lateral flow assay devices and methods for detecting an analyte in a sample which comprises a plurality of nonspecific binding pair members are adapted for two step determinations. In one embodiment, a method for identifying IgE antibodies in a sample comprises applying a sample to a sample port of a device, wherein the device is adapted to deliver the sample to a lateral flow matrix having a plurality of IgE antigen species immobilized at respective positions at a first location, allowing the sample to travel along the lateral flow matrix through the immobilized plurality of IgE antigen species to a second location downstream of the first location and allowing sample to dissolve a water-soluble mark, applying liquid buffer to the lateral flow matrix to mobilize labeled reagent which is adapted to bind anti-IgE antibody and which is dried on the lateral flow matrix at a location upstream of the sample delivery location, and allowing labeled reagent to bind any IgE antibody bound to the immobilized IgE antigen species therein.
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
09 - Scientific and electric apparatus and instruments
10 - Medical apparatus and instruments
Goods & Services
Chemical reagents (other than for medical or veterinary
purposes); diagnostic preparations, other than for medical
or veterinary purposes; diagnostic test kits, not for
medical or veterinary use. Pharmaceutical and veterinary preparations; sanitary
preparations for medical use; dietetic substances adapted
for medical use, food for babies; plasters, materials for
dressings; material for stopping teeth; dental wax;
disinfectants; preparations for destroying vermin;
fungicides, herbicides; chemical reagents for medical or
veterinary use; diagnostic preparations for medical use;
diagnostic tests for medical or veterinary use. Testing apparatus not for medical purposes; diagnostic
apparatus, not for medical purposes. Testing apparatus for medical purposes; diagnostic apparatus
for medical purposes; surgical, medical, dental and
veterinary apparatus and instruments.
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
09 - Scientific and electric apparatus and instruments
10 - Medical apparatus and instruments
Goods & Services
[ Chemical reagents other than for medical or veterinary purposes; diagnostic preparations, other than for medical or veterinary purposes; diagnostic test kits consisting of chemical reagents not for medical or veterinary use ] [ Diagnostic preparations for medical use; diagnostic tests consisting of test strips and washing solutions for medical or veterinary use to detect and measure allergy, asthma and autoimmune diseases ] Diagnostic laboratory apparatus, namely, storage trays, storage inserts, namely inserts for storing diluents and strips, loading trays, laboratory bottles; database management software for laboratory testing analysis Blood testing apparatus for medical purposes
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Chemical reagents and diagnostic preparations; chemical
reagents and diagnostic preparations for in vitro and in
vivo use; all the above mentioned goods for medical or
veterinary purposes. Diagnostic test apparatus for medical and veterinary use.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical, veterinary and sanitary preparations;
dietetic substances adapted for medical use, food for
babies; plaster, material for dressings; material for
stopping teeth, dental wax; disinfectants; preparations for
destroying vermin; fungicides, herbicides.
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
06 - Common metals and ores; objects made of metal
09 - Scientific and electric apparatus and instruments
10 - Medical apparatus and instruments
Goods & Services
(1) Chemical reagents (other than for medical or veterinary purposes); diagnostic preparations, other than for medical or veterinary purposes namely kits consisting of reagents
(2) Diagnostic preparations for medical purposes namely for use in testing, measuring, monitoring allergies, asthma and autoimmune diseases; diagnostic test kits, for medical or veterinary purposes namely for diagnosing allergies, asthma and autoimmune diseases; chemical reagents for medical or veterinary purposes
(3) Diagnostic apparatus for medical purposes namely washers
(4) Diagnostic apparatus for medical purposes namely calibrators, carrier storage trays, storage inserts, dispensers, information management software namely for the management of results of blood sample tests in the field of allergy, asthma and autoimmune diseases testing
(5) Blood test apparatus and instruments for testing, measuring, monitoring and diagnosis of allergies, asthma and autoimmuned diseases for scientific purposes; diagnostic blood test apparatus and instruments for testing, measuring, monitoring and diagnosis of allergies, asthma and autoimmune diseases; testing apparatus for medical purposes namely automated in vitro test system incorporating sample and reagent handling, washing, reading, calculation, integrated processing and printing, storage of calibration curves
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry including chemical reagents and diagnostic preparations for in vitro use in laboratories and industry; chemical substances for preserving foodstuffs. Chemical reagents and diagnostic preparations; chemical reagents and diagnostic preparations for in vitro and in vivo use . Diagnotisc test apparatus for medical and veterinary use.
05 - Pharmaceutical, veterinary and sanitary products
09 - Scientific and electric apparatus and instruments
10 - Medical apparatus and instruments
Goods & Services
(1) Chemical reagents and diagnostic preparations for in vitro use in medical and veterinary purposes and diagnostic preparations for medical and veterinary purposes namely reagents in liquid form for the diagnostic of allergies, asthma, autoimmune diseases; chemical reagents for medical and veterinary purposes; chemical reagents for in vitro use.
(2) Diagnostic tests and diagnostic reagents.
(3) Software used to detect diseases and interpret information.
(4) Diagnostic instruments and apparations namely in vitro test system for medical and veterinary use namely calibrators, dispensers, pipes, carrier racks, trays, microplates, label for samples, sample diluents, microplate covers, sample racks.
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Chemical reagents and diagnostic preparations for in vitro use as an aid in clinical diagnosis in scientific laboratories, in the medical and diagnostic industry Chemical reagents and diagnostic preparations for in vitro use in medical and veterinary laboratories; chemical reagents for medical and veterinary purposes, diagnostic preparations for medical purposes
